<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05042037</url>
  </required_header>
  <id_info>
    <org_study_id>JKEUPM-2021-276</org_study_id>
    <nct_id>NCT05042037</nct_id>
  </id_info>
  <brief_title>Probiotics as Adjunctive Migraine Prophylaxis</brief_title>
  <official_title>The Effectiveness and Tolerability of Multi-Strain Probiotics as Adjunctive Preventive Treatment of Episodic Migraine: A Single Centre, Randomised, Double- Blind, Sham-Controlled Phase 2 Trial (PROBIOTICS -EM).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universiti Putra Malaysia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>B-Crobes Laboratory Sdn. Bhd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universiti Putra Malaysia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the safety and efficacy of multi-strain probiotics as an adjunctive&#xD;
      treatment for episodic migraine&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 2 and single center, randomized, placebo-controlled double-blind clinical&#xD;
      Trial. Episodic migraine patients according to International Headache Society criteria will&#xD;
      be allocated randomly into two treatment arms. One group will receive active probiotics and&#xD;
      another group will receive placebo for treatment phase. Both groups of patients will consume&#xD;
      the treatment twice daily for 12 weeks and assessment will be made at baseline, baseline,&#xD;
      week 4, 8 and 12&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Two-arm parallel assignment involves two groups of participants. One group receives probiotics , and the other group receives placebo.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>The participants, care provider, investigator and outcome assessor of the study is blinded about the allocation status of the participants (Double blinded)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in mean monthly migraine days (MMD).</measure>
    <time_frame>Baseline, week 4, 8 and 12 post treatment</time_frame>
    <description>The MMD will be calculated using the MMD recorded by patients in a headache diary from each of the months of the double-blind treatment phase.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in mean monthly migraine attacks</measure>
    <time_frame>Baseline, week 4, 8 and 12 post treatment</time_frame>
    <description>The mean monthly migraine attacks will be calculated using the monthly migraine attack recorded by patients in headache diaries from each of the months of the double-blind treatment phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction mean monthly migraine days(MMD)</measure>
    <time_frame>12 weeks post treatment</time_frame>
    <description>Proportion of subjects with at least a 50% reduction from baseline in MMD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in mean monthly pain intensity of migraine attacks</measure>
    <time_frame>Baseline, week 4, 8 and 12 post treatment</time_frame>
    <description>The mean monthly pain intensity will be based on the record of the maximal pain intensity by means of a verbal scale (i.e., 0 =no headache; 1 = mild headache; 2 = moderate headache; 3 = severe headache) prior to taking symptomatic medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events in response to probiotics</measure>
    <time_frame>Week 4, 8 and 12 treatment</time_frame>
    <description>Frequency and adverse events in response to (probiotics)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in mean Migraine Induced Disability Assessment Score (MIDAS)</measure>
    <time_frame>Week 0 and 12 post treatment</time_frame>
    <description>Change from baseline in mean Migraine Induced Disability Assessment Score (MIDAS) in migraine patients in response to probiotics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in mean Depression, Anxiety and Stress Scale (DASS21)</measure>
    <time_frame>Week 0 and 12 post treatment</time_frame>
    <description>Change from baseline in mean Depression, Anxiety and Stress Scale (DASS21) score in migraine patients in response to probiotics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in mean Migraine-Specific Quality-of-Life Questionnaire (MSQ V2) score</measure>
    <time_frame>Week 0 and 12 post treatment</time_frame>
    <description>Change from baseline in mean Migraine-Specific Quality-of-Life Questionnaire (MSQ V2) score in migraine patients in response to probiotics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Highly sensitive C-Reactive Protein (hs-CRP)</measure>
    <time_frame>Week 0 and 12 post treatment</time_frame>
    <description>Highly sensitive C-Reactive Protein (hs-CRP) level changes in migraine patients in response to probiotics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Interleukin 6 (IL- 6)</measure>
    <time_frame>Week 0 and 12 post treatment</time_frame>
    <description>Interleukin 6 (IL- 6) level changes in migraine patients in response to probiotics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Tumour Necrosis Factor Alpha (TNF-alpha)</measure>
    <time_frame>Week 0 and 12 post treatment</time_frame>
    <description>Tumour Necrosis Factor Alpha (TNF-alpha) level changes in migraine patients in response to probiotics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction measures of efficacy, tolerability, safety, and expectations of probiotics among the participants</measure>
    <time_frame>Week 0 and 12 post treatment</time_frame>
    <description>A 5-point, Likert scale will be used to evaluate satisfaction with probiotics in migraine prevention</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Migraine</condition>
  <condition>Episodic Migraine</condition>
  <arm_group>
    <arm_group_label>Double-blind, placebo-controlled interventional study</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active treatment group will receive a 3-gram sachet of probiotics containing multi-strain of lactobacillus and Bifidobacterium 30 Colony Forming Unit x 109 to be taken twice daily for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will be given placebo sachet (exactly the same packaging as active comparator) to be taken 1 sachet twice daily for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>(Microbial cell preparation) probiotics</intervention_name>
    <description>Lactobacillus acidophilus (107mg), Lactobacillus casei subsp (107mg), Lactobacillus lactis (107mg), Bifidobacterium bifidum (107mg), Bifidobacterium infantis (107mg) and Bifidobacterium longum (107mg)</description>
    <arm_group_label>Double-blind, placebo-controlled interventional study</arm_group_label>
    <other_name>Granulated Multi-strain Probiotics</other_name>
    <other_name>Hexbio</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo sachet with no microbial cell preparation</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects fulfilling criteria for episodic migraine as per the Third Edition of The&#xD;
             International Headache Society (ICHD-3) (Table 1)&#xD;
&#xD;
          2. Patients diagnosed with episodic migraine (4 or more episodes per month) for a minimum&#xD;
             of 3 months.&#xD;
&#xD;
          3. On a steady treatment regimen: preventive and acute migraine medications and therapies&#xD;
             unchanged over the last 3 months&#xD;
&#xD;
          4. Adult patients Age &gt; 18 years old&#xD;
&#xD;
          5. A signed and dated informed consent document indicating that the subject has been&#xD;
             informed of all pertinent aspects of the study including any known and potential risks&#xD;
             and available alternative treatments.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Lactose intolerance&#xD;
&#xD;
          2. Previous history of small and large bowel surgery&#xD;
&#xD;
          3. Use of probiotics or antibiotics in 2 weeks before baseline visit.&#xD;
&#xD;
          4. Patients with medical conditions such as severe hypertension, infections,&#xD;
&#xD;
          5. Malignancy, cardiovascular and cerebrovascular diseases, epilepsy, degenerative&#xD;
             central nervous system diseases, renal failure, hepatic failure, bleeding diathesis&#xD;
             and serious mental illnesses&#xD;
&#xD;
          6. Headache with red flags symptoms that may suggest organic secondary headaches.&#xD;
&#xD;
          7. Onset of headache more than 50 years&#xD;
&#xD;
          8. Prior GI infection in the previous 3-months&#xD;
&#xD;
          9. Morbid obesity (BMI &gt;40)&#xD;
&#xD;
         10. Pregnant or lactating women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hamidon Basri, AM</last_name>
    <role>Study Chair</role>
    <affiliation>University Putra Malaysia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wan Aliaa Wan Sulaiman, FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Putra Malaysia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Azliza Ibrahim, MMed</last_name>
    <role>Study Director</role>
    <affiliation>Universiti Putra Malaysia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Azliza Ibrahim, MMED</last_name>
    <phone>+60172640768</phone>
    <phone_ext>60134888405</phone_ext>
    <email>azliza.i@upm.edu.my</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hrishikesa Kumar, MBBS</last_name>
    <phone>+0174888979</phone>
    <email>hrishikesa87@ymail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Putra Malaysia</name>
      <address>
        <city>Serdang</city>
        <state>Selangor Darul Ehsan</state>
        <zip>43400</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <contact>
      <last_name>Wan Aliaa Wan Sulaiman, FRCP</last_name>
      <phone>603 8609 2980</phone>
      <email>wanaliaa@upm.edu.my</email>
    </contact>
    <contact_backup>
      <last_name>Azliza Ibrahim, MMed</last_name>
      <phone>0172640768</phone>
      <email>azliza.i@upm.edu.my</email>
    </contact_backup>
    <investigator>
      <last_name>Azliza Ibrahim, MMED</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anna Misyail Rashid, MMED</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Malaysia</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 3, 2021</study_first_submitted>
  <study_first_submitted_qc>September 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2021</study_first_posted>
  <last_update_submitted>September 3, 2021</last_update_submitted>
  <last_update_submitted_qc>September 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universiti Putra Malaysia</investigator_affiliation>
    <investigator_full_name>Wan Aliaa Wan Sulaiman</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <keyword>Episodic migraine, probiotics, effectiveness, preventive treatment, randomized controlled trial.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

